Skip to main content
SpringerLink
Log in

Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex

  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Summary

Chronic but not acute treatment of rats with MAO inhibitory, as with other antidepressant drugs, has been shown to down-regulate the number of cerebro-cortical ß-adrenoceptors. In order to establish whether this effect is associated with an increase in cortical noradrenaline release, rats were treated for 1, 3 or 21 days with clorgyline (2 mg/kg i.p. single injection; 1 mg/kg i.p. repeated injections), and the frontal cortex was then perfused by microdialysis in the awake animal. Control animals were injected with saline.

The concentration of noradrenaline in the microdialysate increased only slightly after 1 or 3 days of clorgyline treatment but increased fourfold over control levels after 21 days treatment. Yohimbine (20 μmol/1) added to the perfusing solution caused a similar degree of enhancement in microdialysate noradrenaline concentration in all groups of rats. Tetrodotoxin (10 μmol/1) reduced noradrenaline concentration to low levels in all groups of animals, but noradrenaline was still detectable in the microdialysate in rats treated with clorgyline for 21 days. Concentrations of the deaminated metabolites dihydroxyphenylacetic acid, dihydroxyphenylglycol and methoxy-hydroxyphenylglycol were lowest after the 21 day clorgyline treatment. Determination of enzyme activity ex vivo showed that MAO-A was inhibited more than 95% by all clorgyline treatments with less than 10% inhibition of MAO-B.

The results indicate that cerebrocortical noradrenaline release increases gradually during chronic MAO inhibition. This may be the result of more complete inhibition of the enzyme with time, not detectable by the ex vivo assay, but shown by the progressive reduction in metabolite levels. The intraneuronal consequence of this effect could be increased vesicular packaging of noradrenaline, together with reduction in net uptake from the synaptic cleft because of increased axoplasmatic noradrenaline levels. Modification of neuronal firing rate may also play a role in the net change in cortical noradrenaline release. The increase in extracellular fluid noradrenaline concentration occurs over a time period similar to that required for ß-adrenoceptor down-regulation, and for the onset of clinical antidepressant action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

DHPG:

dihydroxyphenylglycol

DOPAC:

dihydroxyphenylacetic acid

MHPG:

methoxy-hydroxyphenylglycol

TTX:

tetrodotoxin

MAO:

Monoamine oxidase

References

  • Ari G, Finberg JPM (1992) Effects of clorgyline on the release of noradrenaline from rat vas deferens. Eur J Pharmacol 219:89–96

    Google Scholar 

  • Campbell IC, Murphy DL, Gallagher DW Tallman JF, Marshall EF (1979a) Neurotransmitter-related adaptation in the central nervous system following chronic monoamine oxidase inhibition. In: Singer TP, von Korff RW Murphy DL (eds) Monoamine oxidase: structure, function and altered functions. Academic Press, New York, pp 517–530

    Google Scholar 

  • Campbell IC, Robinson DS, Lovenberg W Murphy DL (1979b) The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. J Neurochem 32:49–55

    Google Scholar 

  • Cassis L, Ludwig J, Grohmann T, Trendelenburg U (1986) The effect of partial inhibition of monoamine oxidase on the steady-state rate of deamination of 3H-catecholamines in two metabolizing systems. Naunyn-Schmiedeberg's Arch Pharmacol 333:253–261

    Google Scholar 

  • Cohen RM, Campbell IC, Cohen MR, Torda T, Pickar D, Siever LJ, Murphy DL (1980) Presynaptic noradrenergic regulation during depression and antidepressant drug treatment. J Psychiat Res 3:93–105

    Google Scholar 

  • Cohen RM, Campbell IC, Dauphin M, Tallman JF, Murphy DL (1982a) Changes in a and ß receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants. Neuropharmacology 21:293–298

    Google Scholar 

  • Cohen RM, Epstein RP, Daly JW Murphy DL (1982b) Chronic effects of a monoamine oxidase-inhibiting antidepressant: decreases in functional α-adrenergic autoreceptors precede the decrease in norepinephrine-stimulated cyclic adenosine 3′:5′ monophosphate systems in rat brain. J Neurosci 2:1588–1595

    Google Scholar 

  • Crews FT, Smith CB (1978) Presynaptic alpha-receptor subsensitivity after long term antidepressant treatment. Science 202:322–324

    Google Scholar 

  • Eisenhofer G, Goldstein DS, Ropchak TG, Nguyen HQ, Keiser HR, Kopin IJ (1988) Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J Autonom Nerv Syst 24:1–14

    Google Scholar 

  • Fillenz M, Stanford SC (1981) Vesicular noradrenaline stores in peripheral nerves of the rat and their modification by tranylcypromine. Br J Pharmacol 73:401–404

    Google Scholar 

  • Finberg JPM (1986) Antidepressant drugs and down-regulation of presynaptic receptors. Biochem Pharmacol 36:3557–3562

    Google Scholar 

  • Finberg JPM, Kopin IJ (1986) Chronic clorgyline treatment enhances release of norepinephrine following sympathetic stimulation in the rat. Naunyn Schmiedeberg's Arch Pharmacol 332:236–242

    Google Scholar 

  • Finberg JPM, Tal A (1985) Reduced peripheral presynaptic adrenoceptor sensitivity following chronic antidepressant treatment in rats. Br J Pharmacol 84:609–617

    Google Scholar 

  • Finberg JPM, Ari G, Lavian G, Hovevey-Sion D (1990) Modification of alpha-2 presynaptic receptor activity and catecholamine release following chronic MAO inhibition. J Neural Transm Suppl 32:405–412

    Google Scholar 

  • Graefe K-H, Bönisch H, Trendelenburg U (1971) Time-dependent changes in neuronal net uptake of noradrenaline after pretreatment with pargyline and/or reserpine. Naunyn-Schmiedeberg's Arch Pharmacol 271:1–28

    Google Scholar 

  • Hovevey-Sion D, Finberg JPM (1987) Chronic inhibition of monoamine oxidase reduces noradrenaline release in rat vas deferens and anococcygeus muscle. Naunyn-Schmiedeberg's Arch Pharmacol 336:70–76

    Google Scholar 

  • Itoh Y, Oishi R, Nishibori M, Saeki K (1990) In vivo measurement of noradrenaline and 3,4-dihydroxyphenylethyleneglycol in the rat hypothalamus by microdialysis: effects of various drugs affecting noradrenaline metabolism. J Pharmacol Exp Ther 255:1090–1097

    Google Scholar 

  • Kopin IJ, Fischer JE, Musacchio JM, Horst WD, Weise VK (1965) False neurochemical transmitters and the mechanism of sympathetic blockade by monoamine oxidase inhibitors. J Pharmacol Exp Ther 147:186–193

    Google Scholar 

  • Lerner P, Major LF, Murphy DL, Lipper S, Lake CR, Lovenberg W (1979) Dopamine beta hydroxylase and norepinephrine in human cerebrospinal fluid: effects of monoamine oxidase inhibitors. Neuropharmacology 18:423–426

    Google Scholar 

  • Lerner P, Major LF, Dendel PS, Campbell IC, Murphy DL (1980) Central and peripheral dopamine beta hydroxylase: responses to long term treatment with monoamine oxidase inhibitors. Neuropharmacology 19:877–881

    Google Scholar 

  • Murphy DL, Lipper S, Campbell IC, Major LF, Slater S, Buchsbaum MS (1979) Comparative studies of MAO-A and MAO-B inhibitors in man. In: Singer TP, von Korff RW Murphy DL (eds) Monoamine oxidase: structure, function and altered functions. Academic Press, New York, pp 457–475

    Google Scholar 

  • O'Carroll A-M, Fowler CJ, Phillips JP, Tobbia I, Tipton KIT (1983) The deamination of dopamine by human brain monoamine oxidase: specificity for the two enzyme forms in seven brain regions. Naunyn-Schmiedeberg's Arch Pharmacol 322:198–202

    Google Scholar 

  • Otsuka S, Kobayashi Y (1964) A radioisotopic assay for monoamine oxidase determinations in human plasma. Biochem Pharmacol 13:995 -1006

    Google Scholar 

  • Pacak K, Armando I, Komoly S, Fukuhara K, Weise V, Holmes C, Kopin IJ, Goldstein DS (1992) Hypercortisolemia inhibits yohimbine-induced release of norepinephrine in the posterolateral hypothalamus of conscious rats. Endocrinology 131:1369–1376

    Google Scholar 

  • Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, San Diego

    Google Scholar 

  • Schömig E, Schonfeld C-L, Halbrügge T, Graefe K-H, Trendelenburg U (1990) The heterogeneity of the neuronal distribution of exogenous noradrenaline in the rat vas deferens. Naunyn-Schmiedeberg's Arch Pharmacol 342:160–170

    Google Scholar 

  • Sellinger-Barnette MM, Mendels J, Frazer A (1980) The effect of psychoactive drugs on beta-adrenergic receptor sites in the brain. Neuropharmacology 19:447–454

    Google Scholar 

  • Sulser F (1978) Functional aspects of the norepinephrine receptor coupled adenylcyclase system in the limbic forebrain and its modification by drugs which precipitate or alleviate depression: molecular approach to an understanding of affective disorders. Pharmakopsychiatrie 11:43–52

    Google Scholar 

  • Thomas DN, Holman RB (1991) A microdialysis study of the regulation of endogenous noradrenaline release in the rat hippocampus. J Neurochem 56:1741–1744

    Google Scholar 

  • Youdim MBH, Finberg JPM (1985) Monoamine oxidase inhibitor antidepressants. In: Grahame-Smith DG, Cohen PJ (eds) Psychopharmacology, vol 1. Excerpta Medica, Amsterdam, pp 38–70

    Google Scholar 

  • Youdim MBH, Finberg JPM, Tipton KIT (1988) Monoamine oxidase. In: Trendelenburg U, Weiner N (eds) Catecholamines, vol 1. Springer, Berlin Heidelberg New York, pp 119–192

    Google Scholar 

Download references

Author information

Author notes

  1. J. PM. Finberg

    Present address: Department of Pharmacology, Bruce Rappaport Faculty of Medicine, Technion, POB 9649, Haifa, Israel

Authors and Affiliations

  1. Clinical Neurochemistry Section, Clinical Neuroscience Branch, N.I.N.D.S., N.I.H., 20892, Bethesda, MD, USA

    J. PM. Finberg, K. Pacak, I. J. Kopin & D. S. Goldstein

Authors
  1. J. PM. Finberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Pacak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. J. Kopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. S. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finberg, J.P., Pacak, K., Kopin, I.J. et al. Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex. Naunyn-Schmiedeberg's Arch Pharmacol 347, 500–505 (1993). https://doi.org/10.1007/BF00166742

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00166742

Key words

Search

Navigation